Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cèlia Rodríguez-Borjabad has a total of 165 co-authors. Here are the top co-authors by number of shared publications:

  • Luis Masana

    Reus Lipid RDI Cluster (LIRIC-URLA), Universitat Rovira i Virgili, IRB CatSud. CIBERDEM, Reus, Spain

    11 shared publications
  • Núria Plana

    Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain

    11 shared publications
  • Daiana Ibarretxe

    6 shared publications
  • Josefa Girona

    Research Unit on Lipids and Atherosclerosis, University Rovira i Virgili, 43201 Reus, Spain

    6 shared publications
  • Albert Feliu

    Pediatric Research Unit, Universitat Rovira I Virgili, IISPV, Reus, Spain

    4 shared publications
  • Daiana Ibarretxe

    Faculty of Medicine, Rovira i Virgili University, Vascular Medicine and Metabolism Unit, “Sant Joan” University Hospital, Pere Virgili Institute for Health Research (IISPV), Biomedical Research Networking Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Avda. Josep Laporte 2, 43204 Reus, Spain

    4 shared publications

Latest Publications

  • Open Access

    Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion

    by Fiona J. White, Javier de Las Heras, Celia Rodríguez-Borjabad, Simon A. Jones, Alexander Y. Kim, Jenna Moore, Florian Abel, Laura Frank, Rosie Jones, Suresh Vijay

    Infantile-onset lysosomal acid lipase deficiency (LAL-D) (Wolman disease, historically) is a rare inherited, rapidly progressive disorder caused by pathogenic variants in the LIPA gene, which encodes the enzyme LAL. LAL is essential for the metabolism of cholesteryl esters and triglycerides. LAL deficiency leads to the accumulation of cholesteryl esters and triglycerides within the lysosomes, macrophages, and parenchymal cells in most tissue types, including those in the liver, gastrointestinal tract, and lymph nodes but excluding the central nervous system. Infants with rapidly progressive LAL-D present with gastrointestinal disturbance, adrenomegaly with calcification, hepatosplenomegaly, growth failure due to malabsorption, and systemic inflammation. If untreated, rapidly progressive LAL-D typically leads to death within the first year of life. Treatment takes the two-pronged approach of sebelipase alfa, a human lysosomal acid lipase enzyme replacement therapy (ERT) that improves lipid metabolism, combined with nutritional management. Dietary substrate (lipid) reduction, known as substrate reduction therapy, is essential for optimal management in LAL-D. Following a nutritional plan and managing gastrointestinal disturbances together reduce systemic inflammation and improve growth, gut function, liver health, quality of life, and survival in patients with infantile-onset LAL-D. A multidisciplinary specialized team is necessary to manage the highly complex, multisystemic conditions in these patients. Nutritional management of LAL-D has evolved with increasing experience with the clinical management of ERT-treated infantile-onset LAL-D. A review of guidance for best practice nutritional management is needed. This narrative review aims to provide updated recommendations and guidance for the optimal nutritional management of infantile-onset LAL-D.


  • Open Access

    Síndrome del Comedor Nocturno: Estrategias crono Nutricionales

    by Jasser Palacios Guzman, Kyara Castro Moreno, Juan Morán Zuloaga, Celia Rodríguez Borjabad, Jestin Quiroz Brunes

    El síndrome de comedor nocturno (SCN) es un trastorno alimentario descrito en el Manual Diagnóstico y Estadístico de los Trastornos Mentales. Se caracteriza por una alteración en el ritmo circadiano de ingesta de alimentos, con una tendencia a comer de manera excesiva por la noche y niveles anormales de melatonina. Los pacientes consumen entre el 50-70% de las calorías diarias después de la cena, presentan anorexia matinal e insomnio acompañado de ingestas nocturnas, con episodios que ocurren al menos una vez por semana durante tres meses consecutivos. El tratamiento del SCN debe ser individualizado, abordando tanto aspectos farmacológicos como no farmacológicos. Se evaluó la efectividad de la ingesta dietética y la suplementación con magnesio y triptófano en el manejo del SCN. A través de una revisión de literatura de los últimos 10 años en la base de datos PubMed, se analizaron 283 artículos, de los cuales se incluyeron 7 para este estudio. Los resultados sugieren que una dieta rica en triptófano o magnesio, así como la suplementación con estos, podría mejorar la calidad del sueño y reducir los episodios de ingesta nocturna en pacientes con insomnio.

  • Open Access

    Lipoprotein profile assessed by 1H NMR, BMI and blood pressure are associated with vascular alterations in children with familial hypercholesterolaemia

    by D. Llop, A. Feliu, D. Ibarretxe, J. Escribano, N. Plana, C. Borjabad-Rodríguez, L. Masana, J.C. Vallvé


  • Glycoprotein Serum Concentrations Assessed By 1H-NMR are Increased in Patients With High Blood Pressure

    by Natalia Andreychuk, Dídac Llop, Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Cèlia Rodríguez-Borjabad, Núria Plana, Lluís Masana

    Background: Patients with hypertension present a permanent state of low-grade inflammation, as the disease activates several pro-inflammatory cells and inflammatory pathways. Glycoproteins A, B, and F, determined by proton nuclear magnetic resonance, provide a highly sensitive method for determining a group of liver-derived pro-inflammatory proteins, and their role has not yet been explored in patients with hypertension. In this study, we evaluated the impact of plasma concentrations of these glycoproteins in patients with hypertension. Methods: This cross-sectional study involved 340 patients attending our vascular and metabolism medicine unit. Of them, 129 were normotensive and 211 were hypertensive. Standard biochemistry and carotid ultrasound measures were performed. Serum concentrations of glycoproteins A, B, and F were determined by proton nuclear magnetic resonance. Results: Hypertensive patients presented a higher prevalence of obesity, metabolic syndrome, and diabetes and higher glycoprotein A, B, and F concentrations. Glycoproteins A, B, and F were positively correlated with systolic and diastolic blood pressure. Multivariate logistic models showed that glycoproteins A, B, and F were associated with higher odds of being hypertensive. Machine learning methods corroborated the relationship between glycoproteins and high blood pressure. The higher prevalence of carotid plaques in patients with high blood pressure was partially mediated by glycoproteins A and F. Conclusions: Patients with hypertension present systemic, subclinical inflammation as assessed by liver-derived glycoprotein A, B, and F serum levels. These results support the effect of hypertension on the mechanisms of systemic inflammation. Hypertension-associated systemic inflammation plays a role in hypertension-associated vascular injury and probably in hypertension-induced damage to other organs.


  • Open Access

    Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study

    by Ana-Irene Malo, Anna Rull, Josefa Girona, Pere Domingo, Rocío Fuertes-Martín, Núria Amigó, Cèlia Rodríguez-Borjabad, Neus Martínez-Micaelo, Manuel Leal, Joaquim Peraire, et al.

    Plasma glycoproteins are a composite biomarker of inflammation and can be detected by 1H-NMR. The aim of this study was to prospectively appraise the clinical value of plasma glycoproteins assessed by 1H-NMR in people living with HIV (PLWH). A total of 221 patients with HIV infection were recruited and studied at baseline and at 48 and 144 weeks. Patients were distributed into two groups according to baseline CD4+ T-cell number below or above 200 cells/µL. Patients with fewer than 200 cells/µL were distributed into the responders and nonresponders according to antiretroviral therapy (ART) response at 144 weeks. Glycoprotein concentrations were determined by 1H-NMR arising from the protein bond N-acetylglucosamine and N-acetylgalactosamine signals (GlycA); and N-acetylneuraminic acid signal (GlycB) associated with the sugar–protein bond concentration and aggregation state (shapes (height/width)). Basal glycoprotein concentrations were higher in patients with < 200 CD4+ T-cell/μL (Glyc A: 1040(917.9–1199.1) vs. 950.4(845.5–1050.9), p < 0.001, and Glyc B: 521(440.3–610.3) vs. 468.6(417.9–507.0) μ mol/L, p < 0.001) being reduced by ART. The height/width (H/W) ratio was the parameter showing a better association with this clinical status. Baseline glycoproteins predict the condition of responder/nonresponder. In this study, 1H-NMR glycoproteins provide novel insights to assess inflammation status and have prognostic value in PLWH.


  • Open Access

    The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario

    by Josefa Girona, Cèlia Rodríguez-Borjabad, Daiana Ibarretxe, Joan-Carles Vallvé, Raimon Ferré, Mercedes Heras, Ricardo Rodríguez-Calvo, Sandra Guaita-Esteruelas, Neus Martínez-Micaelo, Núria Plana, et al.

    Background: Glucose-regulated protein 78/Binding immunoglobulin protein (GRP78/BiP) is a protein associated with endoplasmic reticulum stress and is upregulated by metabolic alterations at the tissue-level, such as hypoxia or glucose deprivation, and it is hyper-expressed in fat tissue of obese individuals. Objective: To investigate the role of the GRP78/BiP level as a metabolic and vascular disease biomarker in patients with type 2 diabetes (DM), obesity and metabolic syndrome (MS). Methods: Four hundred and five patients were recruited, of whom 52.5% were obese, 72.8% had DM, and 78.6% had MS. The intimae media thickness (cIMT) was assessed by ultrasonography. The plasma GRP78/BiP concentration was determined, and its association with metabolic and vascular parameters was assessed. Circulating GRP78/BiP was also prospectively measured in 30 DM patients before and after fenofibrate/niacin treatment and 30 healthy controls. Results: In the cross-sectional study, the GRP78/BiP level was significantly higher in the patients with obesity, DM, and MS. Age-, gender- and BMI-adjusted GRP78/BiP was directly associated with LDL-cholesterol, non-HDL-cholesterol, triglycerides, apoB, and cIMT. GRP78/BiP was positively associated to carotid plaque presence in the adjusted model, irrespective of obesity, DM and MS. In the prospective study, nicotinic acid treatment produced a significant reduction in the GRP78/BiP levels that was not observed with fenofibrate. Conclusions: GRP78/BiP plasma concentrations are increased in patients with both metabolic derangements and subclinical atherosclerosis. GRP78/BiP could be a useful marker of metabolic and cardiovascular risk.


  • Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain

    by Luis Masana, Daiana Ibarretxe, Cèlia Rodríguez-Borjabad, Núria Plana, Pedro Valdivielso, Juan Pedro-Botet, Fernando Civeira, Jose López-Miranda, Carlos Guijarro, Jose Mostaza, et al.


  • Open Access

    HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk

    by Josefa Girona, Núria Amigó, Daiana Ibarretxe, Núria Plana, Cèlia Rodríguez-Borjabad, Mercedes Heras, Raimon Ferré, Míriam Gil, Xavier Correig, Lluís Masana

    While cholesterol content in high-density lipoproteins (HDLs) is a well-established inverse marker of cardiovascular risk, the importance of HDL–triglyceride (HDL-TG) concentration is not well known. We aim to examine plasma HDL-TG concentrations, assessed by 1H-NMR, in patients with metabolic diseases and their association with classical biomarkers. In this cross-sectional study, we included 502 patients with type 2 diabetes or metabolic syndrome attending the lipid unit of our University Hospital. The presence of arteriosclerotic plaques was assessed by ultrasonography. A complete lipoprotein profile was performed by 1H-NMR (Liposcale test). HDL-TG was strongly positively correlated with total triglycerides, glycerol, and fatty liver index, while a strong negative correlation was observed with HDL-cholesterol (HDL-C) and HDL-particle number (HDL-P). HDL-TG was associated with all triglyceride-rich lipoprotein parameters and had an opposite association with HDL-C and HDL-P. It was also significantly correlated with circulating cholesterol ester transfer protein (CETP). HDL-TG concentrations were higher as metabolic syndrome components increased. HDL-TG was also higher with worsening glucose metabolism. Patients with carotid plaques also showed higher HDL-TG. In contrast to HDL-C, HDL-TG is directly associated with metabolism and arteriosclerotic vascular alterations. HDL-TG should be considered a biomarker of metabolic and cardiovascular risk and could be a marker of HDL dysfunction.


  • Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project

    by Daiana Ibarretxe, Cèlia Rodríguez-Borjabad, Albert Feliu, José Ángel Bilbao, Lluís Masana, Núria Plana


  • Valor de los parámetros lipídicos y apoproteicos para la detección de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN

    by Núria Plana, Cèlia Rodríguez-Borjabad, Daiana Ibarretxe, Raimon Ferré, Albert Feliu, Alejandra Caselles, Luis Masana